Certara, Inc.
NasdaqGS:CERT Voorraadrapport
Marktkapitalisatie: US$1.8b
Certara Dividenden en inkoop
Dividend criteriumcontroles 0/6 Certara heeft geen dividenduitkeringen gedaan.
Belangrijke informatie Totaal aandeelhoudersrendement 0.5% Toekomstig dividendrendement 0% Dividendgroei n/a Volgende betaaldatum dividend n/a Ex-dividenddatum n/a Dividend per aandeel n/a Uitbetalingsratio n/a
Recente updates van dividend en inkoop
Toon alle updates
Price target decreased by 10% to US$14.61 Nov 10
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 07
Certara, Inc. Updates Earnings Guidance for the Year 2024 Nov 07
Now 21% overvalued Nov 06
Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued? Oct 24
Certara, Inc. Appoints John Reynders as Independent Board Member Oct 17
Certara, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 10
New minor risk - Profitability Oct 04
Certara, Inc. (NasdaqGS:CERT) completed the acquisition of ChemAxon Kft. Oct 04
Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly Sep 20
Certara: Still Awaiting Consistent Growth Sep 16
Now 22% overvalued Sep 13
President & Chief Commercial Officer notifies of intention to sell stock Sep 11
Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate Aug 31
Certara, Inc. Launches Phoenix™ Version 8.5 Drug Development Software Aug 16
Consensus EPS estimates fall by 317% Aug 13
Price target decreased by 8.8% to US$17.17 Aug 09
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 07
Price target decreased by 9.1% to US$17.72 Aug 07
Certara, Inc. Reiterates Earnings Guidance for the Year 2024 Aug 07
There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price Jul 18
Certara, Inc. (NasdaqGS:CERT)signed a definitive agreement to acquire ChemAxon Kft. Jul 10
Certara, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 04
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software Jun 18
Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital Jun 13
Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel May 22
Certara, Inc. Reiterates Earnings Guidance for the Year 2024 May 09
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 08
Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform Apr 16
Certara, Inc., Annual General Meeting, May 21, 2024 Apr 11
When Should You Buy Certara, Inc. (NASDAQ:CERT)? Apr 11
Certara, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 10
Insider notifies of intention to sell stock Apr 04
Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk Mar 21
Consensus EPS estimates increase by 100% Mar 12
Full year 2023 earnings: EPS misses analyst expectations Mar 01
Certara, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
Returns Are Gaining Momentum At Certara (NASDAQ:CERT) Feb 17
Certara, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 02
Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth Jan 30
Price target increased by 8.3% to US$18.57 Jan 24
Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC. Dec 14
Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT) Dec 07
Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software Nov 22
Certara, Inc. Provides Revenue Guidance for the Year 2023 Nov 10
Price target decreased by 7.5% to US$17.71 Nov 10
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT) Oct 31
Price target decreased by 9.7% to US$18.57 Oct 20
Certara, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 12
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)? Sep 17
President & Chief Commercial Officer notifies of intention to sell stock Sep 13
An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued Aug 30
Consensus EPS estimates fall by 39% Aug 16
Price target decreased by 9.1% to US$21.19 Aug 10
Certara, Inc. Updates Earnings Guidance for the Year 2023 Aug 10
Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue Aug 03
Certara, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 14
Insider notifies of intention to sell stock Jun 09
Consensus EPS estimates fall by 20% May 15
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 10
Certara, Inc. Provides Revenue Guidance for the Year 2023 May 09
CEO & Director exercised options and sold US$370k worth of stock Apr 06
Consensus EPS estimates increase by 11% Mar 14
Consensus EPS estimates increase by 15% Mar 10
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 03
Senior VP notifies of intention to sell stock Feb 06
Certara, Inc. to Report Q4, 2022 Results on Mar 01, 2023 Feb 02
Certara, Inc. (NasdaqGS:CERT) acquired VYASA Analytics LLC. Jan 05
Forecast breakeven date pushed back to 2023 Dec 31
Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company Dec 26 Arsenal Capital Partners completed the acquisition of an additional 18.8% stake in Certara, Inc. (NasdaqGS:CERT) from EQT Avatar Parent L.P.
Certara, Inc. Appoints David Spaight to the Board of Directors Dec 09
President of Software notifies of intention to sell stock Nov 26
Now 22% undervalued after recent price drop Nov 16
Price target decreased to US$20.56 Nov 16
Price target decreased to US$20.56 Nov 13
Third quarter 2022 earnings released: EPS: US$0.025 (vs US$0.012 loss in 3Q 2021) Nov 08 Certara, Inc. Reaffirms Earnings Guidance for the Full Year 2022
Japan's Pharmaceuticals and Medical Devices Agency Renews Licenses of Certara's Software for Evaluating Regulatory Submissions Oct 20
Certara, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 14
Certara: A Story To Watch Sep 27
Insider recently sold US$3.2m worth of stock Aug 18
Now 22% undervalued after recent price drop Aug 17
Certara, Inc. Announces Resignation of Justin Edge as President of Regulatory and Access, Effective September 1, 2022 Aug 13
Certara to raise capital in secondary stock offering Aug 12
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10
Certara, Inc. Revises Its Full Year Earnings Guidance of 2022 Aug 10
Certara, Inc. Introduces Update of Pinnacle 21(Tm) Enterprise and New Pinnacle 21(Tm) Data Exchange Module Aug 06
Certara, Inc. Appoints Rosemary A. Crane, as a Class III Director, Effective July 21, 2022 Jul 26
Certara, Inc. Appoints Eran Broshy as New Independent Board Member, Effective July 11, 2022 Jul 14
Certara, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 13
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development Jun 29
Certara, Inc. Announces New Versions of Biosimulation Software for Development of Novel Biologics Jun 22
Stabiliteit en groei van betalingen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van CERT in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van CERT zijn gestegen.
Dividendrendement versus markt Certara Dividendrendement versus markt
Hoe verhoudt CERT dividendrendement zich tot de markt? Segment Dividendrendement Bedrijf (CERT) n/a Markt onderkant 25% (US) 1.3% Markt Top 25% (US) 4.3% Gemiddelde industrie (Healthcare Services) 1.0% Analist prognose (CERT) (tot 3 jaar) 0%
Opmerkelijk dividend: Het dividendrendement van CERT kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van CERT kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio CERT te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat CERT geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
